Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

Severe neutrophil-dominated inflammation and enhanced myelopoiesis in IL-33-overexpressing CMV/IL33 mice.

Talabot-Ayer D, Martin P, Vesin C, Seemayer CA, Vigne S, Gabay C, Palmer G.

J Immunol. 2015 Jan 15;194(2):750-60. doi: 10.4049/jimmunol.1402057. Epub 2014 Dec 10.

PMID:
25505285
2.

Immune-mediated experimental arthritis in IL-33 deficient mice.

Talabot-Ayer D, Martin P, Seemayer CA, Vigne S, Lamacchia C, Finckh A, Saiji E, Gabay C, Palmer G.

Cytokine. 2014 Sep;69(1):68-74. doi: 10.1016/j.cyto.2014.05.007. Epub 2014 Jun 11.

PMID:
25022964
3.

Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions.

Martin P, Palmer G, Vigne S, Lamacchia C, Rodriguez E, Talabot-Ayer D, Rose-John S, Chalaris A, Gabay C.

J Leukoc Biol. 2013 Oct;94(4):791-802. doi: 10.1189/jlb.0113035. Epub 2013 Jul 1.

4.

The severity of experimental arthritis is independent of IL-36 receptor signaling.

Lamacchia C, Palmer G, Rodriguez E, Martin P, Vigne S, Seemayer CA, Talabot-Ayer D, Towne JE, Gabay C.

Arthritis Res Ther. 2013 Mar 1;15(2):R38. doi: 10.1186/ar4192.

5.

Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency.

Martin P, Talabot-Ayer D, Seemayer CA, Vigne S, Lamacchia C, Rodriguez E, Finckh A, Smith DE, Gabay C, Palmer G.

Arthritis Res Ther. 2013 Jan 16;15(1):R13. doi: 10.1186/ar4143.

6.

Reply to Xie et al. about the article "Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis".

Talabot-Ayer D, Gabay C, Palmer G.

Joint Bone Spine. 2013 Jan;80(1):117-8. doi: 10.1016/j.jbspin.2012.10.007. Epub 2012 Nov 20. No abstract available.

PMID:
23182161
7.

Articular inflammation is controlled by myeloid cell-derived interleukin 1 receptor antagonist during the acute phase of arthritis in mice.

Lamacchia C, Rodriguez E, Palmer G, Vigne S, Martin P, Talabot-Ayer D, Seemayer CA, Gabay C.

Ann Rheum Dis. 2012 Feb;71(2):281-7. doi: 10.1136/annrheumdis-2011-200429. Epub 2011 Nov 9.

PMID:
22072017
8.

The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters.

Talabot-Ayer D, Calo N, Vigne S, Lamacchia C, Gabay C, Palmer G.

J Leukoc Biol. 2012 Jan;91(1):119-25. doi: 10.1189/jlb.0811425. Epub 2011 Oct 19.

9.

IL-36R ligands are potent regulators of dendritic and T cells.

Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, Rodriguez E, Ronchi F, Sallusto F, Dinh H, Sims JE, Gabay C.

Blood. 2011 Nov 24;118(22):5813-23. doi: 10.1182/blood-2011-05-356873. Epub 2011 Aug 22.

10.

Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis.

Talabot-Ayer D, McKee T, Gindre P, Bas S, Baeten DL, Gabay C, Palmer G.

Joint Bone Spine. 2012 Jan;79(1):32-7. doi: 10.1016/j.jbspin.2011.02.011. Epub 2011 Mar 26.

PMID:
21441054
11.

Distinct roles of hepatocyte- and myeloid cell-derived IL-1 receptor antagonist during endotoxemia and sterile inflammation in mice.

Lamacchia C, Palmer G, Bischoff L, Rodriguez E, Talabot-Ayer D, Gabay C.

J Immunol. 2010 Aug 15;185(4):2516-24. doi: 10.4049/jimmunol.1000872. Epub 2010 Jul 16.

12.

Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist.

Lamacchia C, Palmer G, Seemayer CA, Talabot-Ayer D, Gabay C.

Arthritis Rheum. 2010 Feb;62(2):452-62. doi: 10.1002/art.27235.

13.

Expression and function of the NALP3 inflammasome in rheumatoid synovium.

Kolly L, Busso N, Palmer G, Talabot-Ayer D, Chobaz V, So A.

Immunology. 2010 Feb;129(2):178-85. doi: 10.1111/j.1365-2567.2009.03174.x. Epub 2009 Aug 17.

14.

Interleukin-33 is biologically active independently of caspase-1 cleavage.

Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G.

J Biol Chem. 2009 Jul 17;284(29):19420-6. doi: 10.1074/jbc.M901744200. Epub 2009 May 22.

15.

Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.

Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, Finckh A, Smith DE, Gabay C.

Arthritis Rheum. 2009 Mar;60(3):738-49. doi: 10.1002/art.24305.

16.

The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33.

Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, Talabot-Ayer D, Gabay C, Smith DE.

Cytokine. 2008 Jun;42(3):358-64. doi: 10.1016/j.cyto.2008.03.008. Epub 2008 May 2.

PMID:
18450470
17.

Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells.

Moulin D, Donzé O, Talabot-Ayer D, Mézin F, Palmer G, Gabay C.

Cytokine. 2007 Dec;40(3):216-25. Epub 2007 Nov 19.

PMID:
18023358
18.

Expression and function of junctional adhesion molecule-C in human and experimental arthritis.

Palmer G, Busso N, Aurrand-Lions M, Talabot-Ayer D, Chobaz-Péclat V, Zimmerli C, Hammel P, Imhof BA, Gabay C.

Arthritis Res Ther. 2007;9(4):R65.

19.

Type I IL-1 receptor mediates IL-1 and intracellular IL-1 receptor antagonist effects in skin inflammation.

Palmer G, Talabot-Ayer D, Kaya G, Gabay C.

J Invest Dermatol. 2007 Aug;127(8):1938-46. Epub 2007 May 3.

20.

Indirect effects of leptin receptor deficiency on lymphocyte populations and immune response in db/db mice.

Palmer G, Aurrand-Lions M, Contassot E, Talabot-Ayer D, Ducrest-Gay D, Vesin C, Chobaz-Péclat V, Busso N, Gabay C.

J Immunol. 2006 Sep 1;177(5):2899-907.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk